Jagsonpal Pharmaceuticals
- Market cap
- ₹ 1,402 Cr.
- P/E
- 32.2x
- P/B
- 5.11x
- 52-week range
- 155 – 264.5
- ROE
- 17%
- ROCE
- 23%
- Dividend yield
- 1.2%
- Debt / equity
- 0.03
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Jagsonpal Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its Gynaecology products include Divatrone, Endoreg, Cystelia-M, Fibristone, Yuliprist, Deereg, and Lycored Softgel. Its Orthopaedics products include JP Tone Up, Metadec 50 Injection, Metadec 25 Injection, Indocap SR, and Indocap, Colla-2. Its other products include Equirex, Doxypal DR-L, JP Tone Syrup, and Lycored Syrup.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Jagsonpal Pharmaceuticals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)32.2 against a typical 34.3: cheaper than most peers (1st = cheapest).104th of 220
- Sales growth+7.9% against a typical +15.6% from a year earlier.121st of 197
- Profit growth+18.2% against a typical +18.9% from a year earlier.82nd of 160
- Share price, 3 months+2.5% against a typical −0.5%.81st of 200
- Size₹ 1,401.8 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).80th of 199
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 28 Oct 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 29 Jul 2026 | Financial Results | To consider and approve the unaudited financial results for the period ended Jun 30, 2026 |
| 27 Apr 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 12 Mar 2026 | Buyback | To consider buyback for equity shares |
| 21 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 3 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 26 Jul 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 58 | 47 | 43 | 61 | 75 | 74 | 59 | 76 | 74 | 73 | 64 | 82 |
| Expenses | 49 | 44 | 41 | 51 | 58 | 58 | 50 | 61 | 58 | 57 | 53 | 65 |
| Operating Profit | 8 | 3 | 3 | 10 | 16 | 16 | 9 | 14 | 16 | 16 | 11 | 17 |
| OPM % | 14% | 7% | 6% | 17% | 22% | 21% | 15% | 19% | 22% | 22% | 17% | 21% |
| Other Income | 2 | 3 | 2 | −2 | 2 | 26 | 3 | 3 | 3 | 1 | 3 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 10 | 5 | 5 | 7 | 15 | 39 | 9 | 14 | 17 | 15 | 12 | 18 |
| Tax % | 25% | 25% | 22% | 25% | 25% | 17% | 24% | 25% | 25% | 25% | 25% | 25% |
| Net Profit | 7 | 4 | 4 | 5 | 11 | 32 | 7 | 11 | 13 | 11 | 9 | 13 |
| EPS in Rs | 1.14 | 0.6 | 0.54 | 0.81 | 1.73 | 4.82 | 0.99 | 1.62 | 1.89 | 1.64 | 1.31 | 2 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 7%
- 5 Years
- 9%
- 3 Years
- 7%
- TTM
- 4%
- 10 Years
- 30%
- 5 Years
- 21%
- 3 Years
- 16%
- TTM
- 10%
- 10 Years
- 32%
- 5 Years
- 31%
- 3 Years
- 9%
- TTM
- —
- 10 Years
- 12%
- 5 Years
- 17%
- 3 Years
- 17%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Jagsonpal Pharmaceuticals | ₹ 236.20 | ₹ 1,402 Cr. | 32.2x | 5.1x | 17% | — |
| Aurobindo Pharma | ₹ 1,569.30 | ₹ 90,294 Cr. | 25.5x | 2.4x | 9.9% | 10.4% |
| Neuland Laboratories | ₹ 18,882.05 | ₹ 24,132 Cr. | 66.1x | 13x | 21.4% | 18% |
| Pfizer | ₹ 3,610.35 | ₹ 16,513 Cr. | 27.6x | 5x | 17.2% | 28.7% |
| Unichem Laboratories | ₹ 470.00 | ₹ 3,309 Cr. | 54.9x | 1.5x | 9.8% | 11.5% |
| Themis Medicare | ₹ 90.00 | ₹ 826 Cr. | 651.2x | 2.6x | 0.3% | 0.3% |
Management
- Nirav Niranjankumar Vora
- Chief Financial Officer
- Amrut Medhekar
- Chief Operating Officer
- Pratham Rawal
- Compliance Officer, Company Secretary
- Manish Gupta
- Managing Director, Director
Prices are delayed and for information only. Nothing on this page is investment advice.